SRRK Scholar Rock Holding Corp Insider Trading

Scholar Rock CEO Hallal David sold 30,615 shares at $49.57 on 2026-04-16; stock now $47.80, down from 52-week high of $50.01.

David sold 30,615 shares (1.8% of pre-transaction holdings) at $49.57, near the 52-week high of $50.01, while the stock has since declined to $47.80. His cross-ticker track record shows 75.00% well-timed sell performance across 4 prior transactions, but at Scholar Rock specifically, his prior sell on 2026-01-13 was poorly timed, with the stock rising 16.0% in the 90-day period following that sale. Scholar Rock faces structural headwinds: the company posted -$102.2M net income on $33.2M quarterly revenue and reported -100.0% annual revenue growth, indicating a significant business contraction or major earnings miss. The timing of this sale near a 52-week peak, combined with the company's deteriorating fundamentals, warrants investor attention to near-term disclosure and capital allocation decisions.

COO Keith Woods sold 10,220 SRRK shares at $49.57; stock down 4.4% from 52-week high despite +7.1% 30-day rally.

Keith Woods, Chief Operating Officer of Scholar Rock, sold 10,220 shares (10.2K shares) at $49.57 on 2026-04-16 for $506.7K, reducing his holdings from 630.3K to 620.1K shares (-1.6%). The sale occurred near the 52-week high of $50.01 and substantially above the current price of $47.80, suggesting the transaction was executed at a favorable valuation window. Woods' prior sell at this ticker (on 2026-01-13) was followed by a +9.3% 30-day return and +16.0% 90-day return, indicating the stock moved higher after his last open-market sale — a poorly-timed outcome. The company's fundamentals remain concerning: the latest quarter showed $33.2M in revenue against a $-102.2M net loss, with full-year results also negative. This sell-side activity by the COO warrants observation given the company's unprofitability and the insider's prior misstep in timing.

CFO Vikas Sinha sold 10,410 SRRK shares at $49.57 (516.1K) amid -100.0% annual revenue decline and -$102.2M net loss.

CFO Vikas Sinha sold 10,410 shares at $49.57, representing 1.7% of his pre-transaction holdings of 630.3K shares. Scholar Rock is deeply unprofitable, posting a -$102.2M net loss with annual revenue declining -100.0%, and currently trades at $47.80—below the $49.57 transaction price and well below the 52-week high of $50.01. At the same ticker, his prior sell on 2026-01-13 was followed by a 90-day return of +16.0%, indicating poorly-timed exit timing. The CFO's 2 prior cross-ticker sells showed similarly unfavorable timing with a 0.00% well-timed rate, suggesting his historical exit decisions have not preceded stock declines.

President of R&D Vaishnaw sold 12,246 shares at $49.57; stock down 4.4% from 52-week high amid $-102.2M annual loss

Akshay Vaishnaw, President of R&D, sold 12,246 shares (12.2K shares) of Scholar Rock at $49.57 on 2026-04-16, reducing his holdings by 1.9% to 630.5K shares. The sale occurred near the 52-week high ($50.01), with the stock currently down 4.4% from that peak. Scholar Rock posted a quarterly revenue of $33.2M against a full-year net income of $-102.2M, making the company unprofitable with revenue declining 100.0% year-over-year. In Vaishnaw's cross-ticker track record, his 7 prior sells achieved a 90-day well-timed rate of 85.71%; at Scholar Rock specifically, his sole prior sale on 2026-01-13 posted a 90-day return of +16.0%, indicating the stock rose after he sold—a poorly-timed outcome. The current sale near the 52-week high, against the backdrop of severe losses and negative revenue growth, merits investor attention to upcoming quarterly disclosures and R&D efficacy metrics.

CFO Vikas Sinha sells 16,755 shares of SRRK at $42.70; stock up 5.0% in 30 days, +66.5% in 90 days.

Vikas Sinha, CFO of Scholar Rock, sold 16,755 shares (16.8K shares) on 2026-01-13 at $42.70, reducing his holdings from 600,000 to 583,245 shares, a -2.8% reduction. The sale occurred while SRRK was trading near its 52-week highs (-0.7% from $46.87), and the stock has appreciated 5.0% over the prior 30 days and 66.5% over the prior 90 days. Sinha's cross-ticker track record shows 1 prior open-market sale with an average 90-day return of +1022.1% after the sale and a well-timed rate of 0.00%, indicating his prior sales were poorly timed relative to subsequent stock performance. Against a backdrop of strong near-term momentum and a historically poor track record for timing sales, this transaction warrants attention as a data point in the context of the company's unprofitable status (net income of $-102.2M most recent full fiscal year) despite robust revenue growth of +76.4% year-over-year.

COO Keith Woods sold 16,746 shares of SRRK at $42.70, reducing holdings to 583,254 shares as stock rises 5.0% in 30 days.

Keith Woods, Chief Operating Officer, sold 16,746 shares (16.7K shares) for $715,054.20 (715.1K), reducing his stake from 600,000 shares (600.0K shares) to 583,254 shares (583.3K shares) — a 2.8% reduction. The sale occurred at $42.70, below the current price of $46.53 and near the lower bound of the 52-week range ($24.47–$46.87). Scholar Rock is unprofitable with a full-year net income of $-102,220,000.00 ($-102.2M), though it achieved annual revenue growth of +76.4% to $33,193,000.00 ($33.2M) in the latest quarter. The stock has gained 5.0% over the past 30 days and 66.5% over the past 90 days, suggesting near recent-term strength. The sale represents a modest portfolio reduction by a senior executive from a late-stage unprofitable biotech company with strong top-line growth momentum.

SRRK: R&D President Vaishnaw sold 20,438 shares at $42.70 ($872.7K); retains 595.8K shares post-sale.

Akshay Vaishnaw, President of R&D, sold 20,438 shares of Scholar Rock (SRRK) at $42.70, reducing his holdings by 3.3% while retaining 595.8K shares. The sale occurred at a price $3.83 below the current market price of $46.53 and represents a modest position adjustment in a stock that has gained 66.5% over 90 days and risen 5.0% in the past month. Vaishnaw's cross-ticker track record shows a 100.00% well-timed selling rate across six prior transactions—though this metric reflects timing in prior sales and carries no necessary bearing on this specific trade. Scholar Rock remains unprofitable with a $-102.2M net loss in its latest full fiscal year, though the company has achieved strong 76.4% annual revenue growth; the sale occurs against this backdrop of ongoing losses alongside accelerating top-line expansion.

CEO Hallal David sold 57,450 shares of SRRK at $42.70 (Jan 13); holdings now 1,541,645 shares; stock up 66.5% in 90 days despite $-102.2M net loss.

Hallal David, the CEO, sold 57,450 shares for $2,453,115.00, reducing his stake by 3.6% to 1,541,645 shares. This sale occurred at $42.70, notably below the current price of $46.53 and the 52-week high of $46.87, placing the transaction in the upper half of recent trading range despite the stock's +5.0% gain over the prior 30 days and +66.5% surge over 90 days. The company remains unprofitable with a net income of $-102.2M against revenue of $33.2M, though it showed robust 76.4% annual revenue growth. Across his cross-ticker track record, Hallal's prior three sales averaged -1.5% returns over 90 days with a 100.00% well-timed rate, suggesting his historical sells have coincided with subsequent stock weakness; however, this timing pattern cannot be attributed to skill in a discretionary context and warrants monitoring against forward fundamentals and broader market conditions.

Director Akkaraju Srinivas buys 29,599 shares (3 transactions on 2025-10-07) for $1,181,633.67 at SRRK, blended avg $39.92; post-trade holdings 6,367,614 shares (+0.5%)

Akkaraju Srinivas, a director at Scholar Rock Holding Corp, executed 3 separate purchases totaling 29,599 shares for $1,181,633.67 on 2025-10-07, at prices ranging from $39.31 to $40.97. The blended average transaction price of $39.92 compares favorably to the current price of $44.32, and the stock is +18.5% over 30 days and +38.7% over 90 days. However, his prior trades at SRRK tell a cautionary story: 5 recent buys (all within the prior 4 days) have returned -29.2%, -26.1%, -27.6%, -20.8%, and -19.4% at the 30-day mark, with only the most recent outcomes still unmeasurable at 90 days. His cross-ticker track record shows an average 30-day return of -3.2% across 20 prior buys, suggesting a pattern of purchases that have not delivered near-term gains. While the company showed strong revenue growth of +76.4% annually, it remains unprofitable with net income of $-102.2M in the latest full fiscal year, leaving fundamentals unresolved despite the recent stock momentum.

Chief Scientific Officer Qatanani Mo sold 136.5K shares of SRRK at $45.21 for $6.2M, reducing stake by 55.6%.

Qatanani Mo, Chief Scientific Officer of Scholar Rock, executed a substantial reduction of his SRRK stake, selling 136,462 shares at $45.21 on 2025-12-04 for $6,169,788.18. His post-transaction holdings of 108,964 shares represent a 55.6% reduction from his pre-transaction position of 245,426 shares. This sale arrives within a strong price momentum window—the stock is up 60.8% over the past 30 days and 43.3% over 90 days, trading at $45.02 (3.7% below the 52-week high of $46.73). Notably, across his prior four trades at SRRK, each subsequent measurement showed negative 90-day returns (ranging from -8.7% to -15.2%), with all four prior trades proving well-timed; his cross-ticker track record also exhibits a 100.00% well-timed rate on sells. The company remains unprofitable (full-year net income was negative, latest quarterly net income was $-102.2M) despite strong revenue growth of 76.4% annually, a context in which a senior executive's large discretionary sale may signal heightened valuation concerns relative to near-term fundamentals.